Ecologic® ALLERGYCARE formulation inside

Ecologic® ALLERGYCARE is a multispecies probiotic formulation that has shown positive effects in the management of allergic symptoms in children (>1 yr) and adults. The bacterial strains have the capacity to:

  • improve barrier function (level 2)
  • influence the immune system (level 3)
Figure 1: Ecologic® ALLERGYCARE is a multispecies probiotic formulation, able to prevent disturbances on two levels in the gut.
Figure 1: Ecologic® ALLERGYCARE is a multispecies probiotic formulation, able to prevent disturbances on two levels in the gut.

The selected strain combination from the Ecologic® AllergyCare formulation:

  • B. bifidum W23
  • L. acidophilus W55
  • L. casei W56
  • L. salivarius W57
  • Lc. lactis W58

Probiotics formulation for management of allergic symptoms

Worldwide, the prevalence of allergic diseases is rising dramatically in both developed and developing countries. In spite of this escalation, even in the developed world, treatment options for patients with allergic diseases are far from ideal.1 2 3

Allergic diseases are caused by hypersensitivity of the immune system to harmful substances in the environment. Major allergic diseases include asthma, food allergies, allergic rhinitis (AR) and atopic dermatitis (AD) or eczema.

Worldwide, AR currently affects between 10% and 30% of the population and studies indicate that prevalence rates are increasing. AD affects nowadays 15-30% of children and 2-10% of adults.4 Allergic diseases have a high morbidity, are responsible for a substantial proportion of health service use, and are accompanied by a severely reduced quality of life.5

It is not completely clear what triggers the dramatic increases in incidence of allergies, but many theories postulate the involvement of (Westernized) lifestyle, environment and (missing) microbes.6 7 Moreover, the World Allergy Organization and clinical studies, reveal that a reduced biodiversity and alterations in the composition of the gut and skin microbiota are associated with various inflammatory conditions including asthma and allergy.8
Thus, a potential approach to manage allergic symptoms could be the administration of specifically selected probiotic strains.

Figure 2: Major changes in microbial exposure in the first half of the century are believed to trigger the accelerating increase in allergic diseases.
Figure 2: Major changes in microbial exposure in the first half of the century are believed to trigger the accelerating increase in allergic diseases.

Clinical support

Positive findings were established with Ecologic® ALLERGYCARE when tested in a in a double- blind, randomized, placebo-controlled study in children with AD.9 Fourty children between 1-13 years of age received Ecologic® ALLERGYCARE or placebo twice daily for 8 weeks. Both clinical and mechanistic effects were measured at base- line and at the end of the intervention period. Ecologic® ALLERGYCARE significantly reduces the SCORing Atopic Dermatitis (SCORAD) index (p=0.005). These results are supported by the finding that total IgE levels were significantly dropped in the probiotic group, compared to the placebo group. A recent study investigated the effect of Ecologic® ALLERGYCARE on quality of life in patients with AR. In this trial, 40 patients received Ecologic® ALLERGYCARE twice daily for eight weeks. Before and after the intervention period, quality of life was determined using the rhinitis quality of life questionnaire (RQLQ). During the intervention patients also recorded allergic rhinitis symptoms and medication use. . A publication of the study results is expected, the manuscript of the study protocol has been published in the Journal of Alternative and Complementary Medicine.10

Ecologic® ALLERGYCARE publications

  • Watts AM, West NP, et al. Probiotics and Allergic rhinitis: an optimal two-stage design to determine effectiveness. Journal of Alternative and Complementary Medicine; 2016.
  • Yesilova Y, Calka O, et al.Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol 2012;24:189-93.

Safety insurance

The use of oral probiotics has been well researched in many different (incl. vulnerable) patient populations, including infants, elderly people and immunocompromised patients. The general conclusion is that there are no safety risks for the studied bacterial strains in the dosages that were used in the studies. Caution is recommended in a number of highly vulnerable patient populations, such as oncology patients with severe leukopenia or mucositis. Probiotics use in acute pancreatitis is contraindicated. Read More about Safety…
 

World Wide availability

The research formulations of Ecologic® are not sold as consumer products. However our worldwide business partners offer a selection of the formulations their own branded product(s). Thus the specific bacterial compositions can be found in different products around the world.

References

  • 1. Asher MI, Montefort S, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinocon- junctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43.
  • 2. Bowatte G, Lodge C, et al. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. Allergy 2015;70:245-56.
  • 3. Devereux G. The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol 2006;6:869-74.
  • 4. Pawankar R, Holgate ST, et al. WAO White Book on Allergy 2013 Update. World Allergy Organization 2013.
  • 5. Zuberbier T, Lotvall J, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275-9
  • 6. AzadMB,ConeysJG,etal.Probioticsupplementationduring pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ 2013;347:f6471.
  • 7. Kramer A, Bekeschus S, et al. Maintaining health by balancing microbial exposure and prevention of infection: the hygiene hypothesis versus the hypothesis of early immune challenge. The Journal of hospital infection 2013;83 Suppl 1:S29-34.
  • 8. Haahtela T, Holgate S, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Organization Journal 2013;6:3.
  • 9. Watts AM, West NP, et al. Probiotics and Allergic rhinitis: an optimal two-stage design to determine effectiveness. Journal of Alternative and Complementary Medicine; 2016.
  • 10. Yesilova Y, Calka O, et al.Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol 2012;24:189-93.

Formulation ingredients

Bacterial strains

  • B. bifidum W23
  • L. acidophilus W55
  • L. casei W56
  • L. salivarius W57
  • Lc. lactis W58

Ingredients

  • Added: vit B2 & Vit B8